Climedo Blog

Digital Health Bites

Tereza | Customer Success Manager

Tereza | Customer Success Manager at Climedo, January 12, 2022

Three success factors that determine the course of Phase IV trials

When it comes to the quality, benefit and safety (pharmacovigilance) of novel therapies with medicines, do new medicines work better than existing ones? And what side effects or interactions occur in the long term?

CLIMEDO IN THE NEWS

Outsourcing-Pharma: Survey: research industry keen on DCT benefits, slow to adopt Outsourcing-Pharma: Survey seeks to chart adoption of decentralized trials, future plans RAPS: Challenges and opportunities in medical device clinical trials in Europe CenterWatch: European Trials Lag Behind U.S. in Decentralization, Survey Finds Outsourcing-Pharma: Report reveals obstacles to implementing digital trial tech Healthcare Global: A guide to labelling compliance for medical devices Easy Medical Device: EU MDR Survey: What is the Industry’s opinion? RAPS: EU MDR Countdown: Readiness of medtech companies in Europe EPR: How small medical device manufacturers can achieve cost-effective compliant labelling MedTech Dive: EU MDR delay has not made new rules easier to stomach: exec poll RAPS: EU MDR survey: Time investment, costs, and personnel resources Easy Medical Device: What is the cost of an EU MDR project? Podcast: What is the true cost of the EU MDR? MedTech Insight: EU MDR Compliance Will Cost More Than 5% Of Revenues For Half Of Medtechs, Survey Says MedTechDive: EU MDR costing smaller medtechs 5% of their annual sales: survey Zollhof: Climedo’s digital symptom diary supported by Germany’s Federal Ministry of Health Helping MedTech companies comply with EU MDR: A case study Climedo Named Winner of EIT Health’s Headstart Program Medical Plastics News: How Covid-19 is impacting the medtech industry Survey results suggest medtech companies are not ready for EU MDR EIT Health: COVID-19 – Response from EIT Health Germany community